As of Nov 20
| -0.29 / -0.50%|
The 7 analysts offering 12-month price forecasts for Haemonetics Corp have a median target of 51.00, with a high estimate of 59.00 and a low estimate of 47.00. The median estimate represents a -11.61% decrease from the last price of 57.70.
The current consensus among 9 polled investment analysts is to Hold stock in Haemonetics Corp. This rating has held steady since November, when it was downgraded from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.